Drug Patents owned by Acrotech

1. Drug name - BELEODAQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6888027 ACROTECH Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
Aug, 2026

(3 years from now)

EP1328510B1 ACROTECH (E)-N-Hydroxy-3-(3-Sulfamoyl-Phenyl)-Acrylamide Compounds And Their Therapeutic Use
Sep, 2021

(a year ago)

EP1328510A2 ACROTECH (E)-N-Hydroxy-3-(3-Sulfamoyl-Phenyl)-Acrylamide Compounds And Their Therapeutic Use
Sep, 2021

(a year ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835501 ACROTECH Pharmaceutical formulations of HDAC inhibitors Oct, 2027

(5 years from now)

Drugs and Companies using BELINOSTAT ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
500MG/VIAL POWDER;INTRAVENOUS Prescription

2. Drug name - EVOMELA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9200088 ACROTECH Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US8410077 ACROTECH Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US11020363 ACROTECH Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same May, 2030

(7 years from now)

US10864183 ACROTECH Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same May, 2030

(7 years from now)

US10940128 ACROTECH Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same Jun, 2030

(7 years from now)

US9493582 ACROTECH Alkylated cyclodextrin compositions and processes for preparing and using the same Feb, 2033

(10 years from now)

US10040872 ACROTECH Alkylated cyclodextrin compositions and processes for preparing and using the same Jan, 2034

(11 years from now)

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Treatment: For high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE/VIAL POWDER;INTRAVENOUS Prescription

3. Drug name - FOLOTYN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6028071 ACROTECH Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors
Jul, 2022

(2 months ago)

EP944389A1 ACROTECH Purified Compositions Of 10-Propargyl-10-Deazaaminopterin And Methods Of Using Same In The Treatment Of Tumors
Jul, 2017

(5 years ago)

EP944389B1 ACROTECH Purified Compositions Of 10-Propargyl-10-Deazaaminopterin And Methods Of Using Same In The Treatment Of Tumors
Jul, 2017

(5 years ago)

EP944389A4 ACROTECH Purified Compositions Of 10-Propargyl-10-Deazaaminopterin And Methods Of Using Same In The Treatment Of Tumors
Jul, 2017

(5 years ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7622470 ACROTECH Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin May, 2025

(2 years from now)

US8299078 ACROTECH Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin May, 2025

(2 years from now)

Drugs and Companies using PRALATREXATE ingredient

Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
20MG/ML (20MG/ML) SOLUTION;INTRAVENOUS Prescription
40MG/2ML (20MG/ML) SOLUTION;INTRAVENOUS Prescription

4. Drug name - FUSILEV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6500829 ACROTECH Substantially pure diastereoisomers of tetrahydrofolate derivatives
Mar, 2022

(6 months ago)

EP608002B1 ACROTECH Optically Active Compounds
Sep, 2007

(15 years ago)

EP266042A3 ACROTECH Optically Active Pteridine Derivatives
Sep, 2007

(15 years ago)

EP608002A1 ACROTECH Optically Active Compounds
Sep, 2007

(15 years ago)

EP266042A2 ACROTECH Optically Active Pteridine Derivatives
Sep, 2007

(15 years ago)

EP266042A1 ACROTECH Optically Active Pteridine Derivatives
Sep, 2007

(15 years ago)

EP1275393A1 ACROTECH Pharmaceutical Formulation Containing Pteridine Derivative
Sep, 2007

(15 years ago)

EP266042B1 ACROTECH Optically Active Pteridine Derivatives
Sep, 2007

(15 years ago)

EP1275393B1 ACROTECH Pharmaceutical Formulation Containing Pteridine Derivative
Sep, 2007

(15 years ago)

Drugs and Companies using LEVOLEUCOVORIN CALCIUM ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE/VIAL POWDER;INTRAVENOUS Prescription
EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Discontinued
EQ 250MG BASE/25ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Discontinued

availability in other generic markets.

Click on the highlighted region to filter.